Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced that the U.S. FDA has granted Priority Review for a supplemental Biologics License Application for the perioperative use of PADCEV in combination with Keytruda, targeting Muscle-Invasive Bladder Cancer (MIBC). This filing aims to broaden the treatment indication to all patients, irrespective of cisplatin eligibility, following the initial approval for cisplatin-ineligible patients in November 2025.
The implications for the financial markets are significant. The Phase III EV-304 study demonstrated that the combination therapy reduced the risk of tumor recurrence, progression, or death by 47%, and the risk of death by 35% compared to standard chemotherapy. With a PDUFA target action date set for August 17, 2026, successful approval could bolster Astellas and Pfizer’s market positions in oncology, potentially impacting stock performance and investor sentiment in the biotech sector.
Market professionals should monitor this development closely, as the expanded indication could enhance revenue streams for both companies and influence broader trends in cancer treatment paradigms.
Source: nasdaq.com